TCGA-AR-A0U2-01A-11R-A109-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 85
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.620
- G2M_CHECKPOINT+0.600
- MITOTIC_SPINDLE+0.440
- PROTEIN_SECRETION+0.350
- MYC_TARGETS_V1+0.300
- PI3K_AKT_MTOR_SIGNALING+0.290
- MYC_TARGETS_V2+0.270
- SPERMATOGENESIS+0.270
- MTORC1_SIGNALING+0.200
- HEDGEHOG_SIGNALING+0.160
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.570
- ANGIOGENESIS-0.520
- NOTCH_SIGNALING-0.480
- COAGULATION-0.440
- TNFA_SIGNALING_VIA_NFKB-0.440
- MYOGENESIS-0.430
- HYPOXIA-0.370
- INFLAMMATORY_RESPONSE-0.370
- IL6_JAK_STAT3_SIGNALING-0.350
- P53_PATHWAY-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR650141 | — | — | 0.896 |
| 2 | MDT-AP-0314 | Med | Medulloblastoma | 0.893 |
| 3 | MDT-AP-3021 | Med | Medulloblastoma | 0.891 |
| 4 | MDT-AP-0188 | Med | Medulloblastoma | 0.885 |
| 5 | MDT-AP-2917 | Med | Medulloblastoma | 0.884 |
| 6 | BS_8QB4S4VA | Embryonal tumors | — | 0.884 |
| 7 | BS_4CP4T22V | medulloblastoma | — | 0.877 |
| 8 | SJEPD031150_D1.RNA-Seq | EPN | EPN Tumor | 0.876 |
| 9 | BS_HF3RNN2T | medulloblastoma | — | 0.876 |
| 10 | SRR1797285 | — | cohortSC | 0.869 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.620 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.600 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.440 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.350 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.290 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.270 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.270 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.160 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.140 | Cobimetinib | — uncovered |
| HEME_METABOLISM | 0.040 | Temsirolimus | — uncovered |
| DNA_REPAIR | 0.030 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.020 | Idelalisib | — uncovered |